Aspirin Population For MI Prevention Rests On “Floating” Factors – Temple
This article was originally published in The Tan Sheet
Executive Summary
Bayer will have to bolster its evidence that aspirin use has an actual benefit for primary prevention of myocardial infarction, the firm was told during an April 30 FDA feedback meeting
You may also be interested in...
Bayer Will Submit More Data To FDA On Aspirin MI Prevention Labeling
Bayer will submit additional data on subpopulation risks associated with aspirin therapy to support its citizen petition requesting amended professional labeling for primary prevention of myocardial infarction
Non-Fatal MI Prevention Indication For Aspirin May Cause Bayer Less Pain
Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC